Last update Sept. 4, 2022

Granisetron

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Antiemetic and antinauseous used in the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy, radiotherapy and in the postoperative period. Intravenous administration in one or two daily doses.

At the date of the last update we did not find any published data on its excretion in breast milk.

Its pharmacokinetic data do not allow a good prediction of its possible excretion in breast milk, since while its low protein binding, low molecular weight and high pKA would facilitate it (Pistilli 2013), its very large volume of distribution would make it difficult.

Although some author considers it probably compatible (Mahadevan 2006), until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable (Pistilli 2013), especially during the neonatal period and in the event of prematurity.

Alternatives

  • Domperidone ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Metoclopramide ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Ondansetron ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Granisetron is also known as


Granisetron in other languages or writings:

Groups

Granisetron belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Granisetron in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 60 %
Molecular weight 312 daltons
Protein Binding 65 %
VD 3 l/Kg
pKa 14.75 -
Tmax 1 hours
4 - 12 hours

References

  1. AEMPS. Granisetrón. Ficha técnica. 2017 Full text (in our servers)
  2. Mylan Ph. Granisetron. Drug Summary. 2014 Full text (in our servers)
  3. Pistilli B, Bellettini G, Giovannetti E, Codacci-Pisanelli G, Azim HA Jr, Benedetti G, Sarno MA, Peccatori FA. Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: how should we counsel cancer patients about breastfeeding? Cancer Treat Rev. 2013 May;39(3):207-11. Abstract
  4. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006 Jul;131(1):283-311. Review. Abstract Full text (link to original source) Full text (in our servers)

Total visits

4,361

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM